The core components of CRISPR-based genome-editing therapies are bacterial proteins called nucleases that can stimulate ...

Metagenomi says it hopes to start clinical trials next year to test MGX-001, its gene-editing therapy candidate for ...

Adjust the ionic composition and pH of the reaction mixture to suit the restriction enzyme, add 20 units of ... Rapidly add 300 μl of ice-cold nuclease S1 digestion buffer and immediately remove ...

"By enhancing our CRISPR expertise with AstraZeneca's novel nuclease, we are poised to expedite ... upfront fees for rights to a leading CRISPR enzyme enabling therapeutic developers to de-risk ...

Synthego granted global license to manufacture and distribute AZ's CRISPR gene editing enzyme, eSpOT-ON.

For its wholly owned in vivo programs, Precision is developing an ARCUS nuclease that targets chronic ... from a naturally occurring gene-editing enzyme with unique specificity, precision, and ...

This state-of-the-art nuclease, developed by AstraZeneca ... significantly lower upfront fees for rights to a leading CRISPR enzyme enabling therapeutic developers to de-risk their fundraising ...